Interestingly, DVL1 amplification and over-expression were observed in breast and prostate cancers respectively [87,88], while DVL3 mRNA was significantly increased in pleural effusions from patients with lung cancer [89] and was over-expressed in NSCLC [90,91]. This evidence concerns the gene DVL1 and prostate carcinoma.